Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
LymphomaMyelomaLeukemia
Interventions
BIOLOGICAL

NK-Cell Infusion

The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.

Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

Tufts Medical Center

OTHER

NCT00660166 - Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | Biotech Hunter | Biotech Hunter